PLIANT THERAPEUTICS INC (PLRX)

Company Profile

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 158 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The firm has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. The company has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. The company has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The firm has a preclinical program, PLN-101325, targeting muscular dystrophies.

Company Info

PLIANT THERAPEUTICS INC

331 Oyster Point Boulevard

South San Francisco CALIFORNIA 94080

P: 16504816770

CEO: Bernard Coulie

Employees: 166

Website: https://pliantrx.com/